Literature DB >> 21389255

Functional plasticity of antigen-specific regulatory T cells in context of tumor.

Caroline Addey1, Matthew White, Lang Dou, David Coe, Julian Dyson, Jian-Guo Chai.   

Abstract

Although polyclonal regulatory T cells (Tregs) that once expressed Foxp3 (ex-Tregs) derived from Foxp3(+) Tregs have been described in homeostatic and autoimmune settings, little is known regarding the influence of the tumor environment on ex-Treg development. After adoptive transfer of HY-specific green Tregs (peripheral or thymic) to Rag2(-/-) B6 female mice bearing syngeneic HY-expressing MB49 tumors, a significant fraction rapidly lost expression of Foxp3. On the second transfer to a Rag2(-/-) B6 male environment, these ex-Tregs expanded strongly, whereas Tregs that maintained expression of Foxp3 expression did not. Both FACS and quantitative real-time-PCR analysis revealed that ex-Tregs upregulated genes characteristic of a Th1 effector-memory phenotype including IFN-γ and downregulated a panel of Treg-specific genes. Peripheral HY-specific green Tregs were adoptively transferred to Rag2(-/-) B6 male mice, to dissect the factors regulating ex-Treg differentiation. Development of ex-Tregs was more efficient in the mesenteric lymph node (mLN) than peripheral lymph node environment, correlating with a much greater level of IL-6 mRNA in mLN. In addition, the preferential development of ex-Tregs in mLN was significantly impaired by cotransfer of HY-specific naive CD4 T cells. Collectively, our study not only demonstrates the plasticity of Ag-specific Tregs in the context of the tumor environment, but also defines key molecular and cellular events that modulate ex-Treg differentiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389255     DOI: 10.4049/jimmunol.1003797

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.

Authors:  Theresa L Whiteside
Journal:  Cancer Microenviron       Date:  2014-11-12

Review 2.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 3.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

4.  Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Authors:  Brian M Olson; Ewa Jankowska-Gan; Jordan T Becker; Dario A A Vignali; William J Burlingham; Douglas G McNeel
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

5.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

Authors:  Madhav D Sharma; Lei Huang; Jeong-Hyeon Choi; Eun-Joon Lee; James M Wilson; Henrique Lemos; Fan Pan; Bruce R Blazar; Drew M Pardoll; Andrew L Mellor; Huidong Shi; David H Munn
Journal:  Immunity       Date:  2013-05-16       Impact factor: 31.745

6.  Monitoring regulatory immune responses in tumor immunotherapy clinical trials.

Authors:  Brian M Olson; Douglas G McNeel
Journal:  Front Oncol       Date:  2013-05-06       Impact factor: 6.244

7.  Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo.

Authors:  Daisuke Sugiura; Kaori Denda-Nagai; Mitsuyo Takashima; Ryuichi Murakami; Shigenori Nagai; Kazuyoshi Takeda; Tatsuro Irimura
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

8.  Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells.

Authors:  Magis Mandapathil; Carmen Visus; Olivera J Finn; Stephan Lang; Theresa L Whiteside
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

9.  Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.

Authors:  Chiara Camisaschi; Paola Filipazzi; Marcella Tazzari; Chiara Casati; Valeria Beretta; Lorenzo Pilla; Roberto Patuzzo; Andrea Maurichi; Agata Cova; Michele Maio; Vanna Chiarion-Sileni; Gabrina Tragni; Mario Santinami; Barbara Vergani; Antonello Villa; Emilio Berti; Ludmila Umansky; Philipp Beckhove; Viktor Umansky; Giorgio Parmiani; Licia Rivoltini; Chiara Castelli
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

10.  Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP.

Authors:  Eyad Elkord; May Abd Al Samid; Belal Chaudhary
Journal:  Oncotarget       Date:  2015-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.